

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

Hydroxychloroquine and ivermectin: A synergistic combination for COVID-19 chemoprophylaxis and treatment?



To the Editor: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has spread all over the world. While awaiting a vaccine, we need effective drugs to treat or, even better, prevent coronavirus disease-19 (COVID-19). Two drugs classically used by dermatologists are being examined in the fight against COVID-19: hydroxychloroquine (HCQ), and, very recently, ivermectin. We hypothesize that HCQ and ivermectin may show a consequential and synergistic action if administered simultaneously both for chemoprophylaxis and treatment of COVID-19.

HCQ is an antimalarial drug, an analog of chloroquine (CQ), considered as an immunomodulator rather than immunosuppressant. HCQ and CQ inhibit SARS-CoV-2 in vitro, with HCQ found to be more potent than chloroquine (CQ). HCQ has shown antiviral effects at both preinfection and postinfection stages. Indeed, HCQ could interfere with the glycosylation of angiotensin-converting enzyme 2, thereby reducing the binding efficiency between angiotensin-converting enzyme 2 on host cells and the SARS-CoV-2 spike protein. Moreover, HCQ could be able to block virus fusion with the host cell through the inhibition of protease activity in cleaving coronavirus surface spike proteins.

Significantly, HCQ contributes to the suppression of the "cytokine storm" responsible for the disease progression to acute respiratory distress syndrome by several mechanisms, including the reduction of T-cell activation and differentiation as well as decreased production of cytokines by T cells and B cells. Several studies in vivo are underway to assess HCQ effectiveness on SARS-CoV-2 infection, with promising preliminary results.

Ivermectin is an antiparasitic drug, classically prescribed at our dermatologic clinic as first-line treatment for cutaneous larva migrans. Interestingly, it also displayed an antiviral activity. Indeed, ivermectin acts as a specific inhibitor of importin- $\alpha/\beta-$ mediated nuclear import. Thus, by impacting on importin- $\alpha/\beta-$ dependent nuclear transport of viral proteins, ivermectin suppresses the replication of several RNA viruses, including HIV, chikungunya virus, and yellow fever virus. 3

Very recently, Caly et al⁴ demonstrated antiviral action of ivermectin against the SARS-CoV-2 clinical isolate in vitro, with a single dose of the drug able to control viral replication within 24 to 48 hours. The authors hypothesized that such results were likely due to the inhibition of importin- α/β 1—mediated

nuclear import of viral proteins, as shown for other RNA viruses.⁴ However, no study with ivermectin in vivo has been conducted.

Based on all such evidence, we hypothesize that HCQ and ivermectin could act in a consequential and synergistic manner. Indeed, HCQ would behave as a first-level barrier by inhibiting the entry of the virus into the host cell, while ivermectin could reduce viral replication if the virus did get in, strengthening HCQ antiviral effects. HCQ is cheap to produce and safe if monitored properly. Ivermectin seems to be safe and well tolerated, with no serious drug-related adverse events.⁵ Moreover, the 2 drugs do not seem to have a between-drug interaction. However, no in vitro or in vivo studies have been conducted on the combined effect of HCQ and ivermectin on SARS-CoV-2 infection. Ours is only a hypothesis and a suggestion, but if not now, when should researchers share ideas?

Angela Patrì, MD, and Gabriella Fabbrocini, MD

From the Section of Dermatology and Venereology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy.

Funding sources: None.

Conflicts of interest: None disclosed.

IRB approval status: Not applicable.

Reprints not available from the authors.

Correspondence to: Angela Patrì, MD, Department of Clinical Medicine and Surgery, Section of Dermatology and Venereology, University of Naples Federico II, Via Pansini 5, 80131 Naples, Italy

E-mail: patriangela.ap@gmail.com

REFERENCES

- Zhou D, Dai SM, Tong Q. COVID-19: a recommendation to examine the effect of hydroxychloroquine in preventing infection and progression. J Antimicrob Chemother. 2020:dkaa114.
- Yao X, Ye F, Zhang M, et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020:ciaa237.
- Lv C, Liu W, Wang B, et al. Ivermectin inhibits DNA polymerase UL42 of pseudorabies virus entrance into the nucleus and proliferation of the virus in vitro and vivo. Antiviral Res. 2018;159:55-62.
- Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM. The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro. *Antiviral Res.* 2020. https://doi.org/ 10.1016/j.antiviral.2020.104787.
- Sanz-Navarro J, Feal C, Dauden E. Treatment of human scabies with oral ivermectin. eczematous eruptions as a new non-reported adverse event. Actas Dermosifiliogr. 2017;108(7):643-649.

https://doi.org/10.1016/j.jaad.2020.04.017